Topics

Shionogi & Co., Hsiri Therapeutics Expand Infectious Diseases Alliance

04:59 EDT 11 Oct 2019 | Contract Pharma

Shionogi will have exclusive worldwide rights to develop, manufacture, and commercialize the compounds generated from the collaboration

Original Article: Shionogi & Co., Hsiri Therapeutics Expand Infectious Diseases Alliance

NEXT ARTICLE

More From BioPortfolio on "Shionogi & Co., Hsiri Therapeutics Expand Infectious Diseases Alliance"

Quick Search

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...